Integrating POLE / POLD1 mutated for immunotherapy treatment planning of advanced stage non‐small cell lung cancer

BACKGROUND: In this study, we evaluated the potential of DNA polymerase epsilon (POLE) and DNA polymerase delta 1 (POLD1) as prognostic biomarkers for immune checkpoint inhibitor (ICI) treatment in patients with advanced stage non‐small cell lung cancer (NSCLC). METHODS: Disease stage, PD‐L1 positiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shuhua, Cao, Yenong, Randall, James, Yu, Haomin, Thomas, Tarita O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423654/
https://www.ncbi.nlm.nih.gov/pubmed/37345618
http://dx.doi.org/10.1111/1759-7714.15012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423654/
https://www.ncbi.nlm.nih.gov/pubmed/37345618
http://dx.doi.org/10.1111/1759-7714.15012

Ejemplares similares